Read More

Daré Bioscience Highlights Efficacy Data From Treatment Candidate For Painful Menstruation

Daré Bioscience Inc (NASDAQ: DARE) announced topline results from the Phase 1 DARE-PDM1-001 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1 an investigational product designed to deliver diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), vaginall

DARE